CD274 and neoplasm: In case of chemotherapy failure, nivolumab acted as a third‐line therapy in the context of negative PD‐L1 expression, resulting in a dramatic regression of tumor size to an almost undetectable level, with efficacy sustained for approximately 22 months [21].